<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kim HJ</submitter><funding>NIA NIH HHS</funding><pagination>93-109</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10939110</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>28(1)</volume><pubmed_abstract>Myeloid ecotropic virus insertion site 1 (&lt;i>MEIS1&lt;/i>) is a HOX co-factor necessary for organ development and normal hematopoiesis. Recently, &lt;i>MEIS1&lt;/i> has been linked to the development and progression of various cancers. However, its role in gliomagenesis particularly on glioma stem cells (GSCs) remains unclear. Here, we demonstrate that &lt;i>MEIS1&lt;/i> is highly upregulated in GSCs compared to normal, and glioma cells and to its differentiated counterparts. Inhibition of &lt;i>MEIS1&lt;/i> expression by shRNA significantly reduced GSC growth in both &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i> experiments. On the other hand, integrated transcriptomics analyses of glioma datasets revealed that &lt;i>MEIS1&lt;/i> expression is correlated to cell cycle-related genes. Clinical data analysis revealed that &lt;i>MEIS1&lt;/i> expression is elevated in high-grade gliomas, and patients with high &lt;i>MEIS1&lt;/i> levels have poorer overall survival outcomes. The findings suggest that &lt;i>MEIS1&lt;/i> is a prognostic biomarker for glioma patients and a possible target for developing novel therapeutic strategies against GBM.</pubmed_abstract><journal>Animal cells and systems</journal><pubmed_title>The impact of &lt;i>MEIS1&lt;/i> TALE homeodomain transcription factor knockdown on glioma stem cell growth.</pubmed_title><pmcid>PMC10939110</pmcid><funding_grant_id>R01 AG068179</funding_grant_id><funding_grant_id>R56 AG082796</funding_grant_id><pubmed_authors>Lee S</pubmed_authors><pubmed_authors>Jeon YJ</pubmed_authors><pubmed_authors>Beck S</pubmed_authors><pubmed_authors>Kim SH</pubmed_authors><pubmed_authors>Kim HJ</pubmed_authors><pubmed_authors>Batara DC</pubmed_authors></additional><is_claimable>false</is_claimable><name>The impact of &lt;i>MEIS1&lt;/i> TALE homeodomain transcription factor knockdown on glioma stem cell growth.</name><description>Myeloid ecotropic virus insertion site 1 (&lt;i>MEIS1&lt;/i>) is a HOX co-factor necessary for organ development and normal hematopoiesis. Recently, &lt;i>MEIS1&lt;/i> has been linked to the development and progression of various cancers. However, its role in gliomagenesis particularly on glioma stem cells (GSCs) remains unclear. Here, we demonstrate that &lt;i>MEIS1&lt;/i> is highly upregulated in GSCs compared to normal, and glioma cells and to its differentiated counterparts. Inhibition of &lt;i>MEIS1&lt;/i> expression by shRNA significantly reduced GSC growth in both &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i> experiments. On the other hand, integrated transcriptomics analyses of glioma datasets revealed that &lt;i>MEIS1&lt;/i> expression is correlated to cell cycle-related genes. Clinical data analysis revealed that &lt;i>MEIS1&lt;/i> expression is elevated in high-grade gliomas, and patients with high &lt;i>MEIS1&lt;/i> levels have poorer overall survival outcomes. The findings suggest that &lt;i>MEIS1&lt;/i> is a prognostic biomarker for glioma patients and a possible target for developing novel therapeutic strategies against GBM.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-06-27T03:10:39.545Z</modification><creation>2026-06-27T03:05:40.888Z</creation></dates><accession>S-EPMC10939110</accession><cross_references><pubmed>38487309</pubmed><doi>10.1080/19768354.2024.2327340</doi></cross_references></HashMap>